trending Market Intelligence /marketintelligence/en/news-insights/trending/wdqhalfri53n_0swtoypaq2 content esgSubNav
In This List

Vertex chief medical officer retiring; Swedish Orphan to welcome new CFO

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Vertex chief medical officer retiring; Swedish Orphan to welcome new CFO

S&P Global Market Intelligence presents a weekly rundown of recent executive changes at pharmaceutical, biotech and life sciences companies.

* Vertex Pharmaceuticals Inc. said Jeffrey Chodakewitz will retire as the company's chief medical officer and executive vice president of global medicines development and medical affairs but will remain in an advisory role through early 2019. He will be replaced by Reshma Kewalramani, the company's senior vice president of clinical development and medical affairs, on April 1.

* Sumitomo Dainippon Pharma Co. Ltd. said President and CEO Masayo Tada will transition to the company's chairman role. Hiroshi Nomura, the drugmaker's executive vice president, will take over the president and CEO roles. Both appointments are effective April 1.

* Recipharm AB CFO Henrik Stenqvist is moving to Swedish Orphan Biovitrum AB to serve in the same capacity. Stenqvist will replace Mats-Olof Wallin, who will support the transition process at Swedish Orphan and retire by the end of the year.

* Orexigen Therapeutics Inc. Executive Vice president and CFO Jason Keyes resigned. The company named its senior director of financial planning and analysis, Monica Forbes, as vice president and acting CFO.

* Clearside BioMedical Inc. appointed Brion Raymond to the newly created position of chief commercial officer. Concurrently, Christy Shaffer resigned as the company's chairperson but will continue to serve as a board member. She will be replaced by William Humphries, a director of the company, as chairperson.

* Paul Lytle is voluntarily resigning as CFO of Avid Bioservices Inc. Lytle's resignation will be effective 90 days from his Feb. 23 notice. The company is starting a search for its next CFO.